Last updated: April 6, 2026

Hemangiosarcoma in Dogs: A Complete Cancer Guide

Hemangiosarcoma is one of the most feared cancer diagnoses a dog owner can receive. This aggressive cancer of the blood vessel lining can develop silently, often going undetected until it reaches an advanced stage or causes a life-threatening emergency. Despite its severity, understanding hemangiosarcoma can help you make informed decisions about your dog’s care and ensure their comfort throughout treatment.

In this guide, we explain what hemangiosarcoma is, which dogs are most at risk, how it is diagnosed and treated, and what you can do to support your dog through this difficult journey.

What Is Hemangiosarcoma?

Hemangiosarcoma (HSA) is a malignant cancer that originates from the endothelial cells — the cells that line blood vessels. Because blood vessels are found throughout the entire body, hemangiosarcoma can develop virtually anywhere. However, it most commonly affects three primary locations:

• Spleen (splenic hemangiosarcoma) — This is the most common form, accounting for approximately 50% to 65% of all hemangiosarcoma cases. The spleen is a blood-rich organ, making it particularly susceptible. Tumors in the spleen can grow to a significant size before causing noticeable symptoms.
• Heart (cardiac hemangiosarcoma) — The right atrium of the heart is the second most common site. Tumors here can cause fluid to accumulate around the heart (pericardial effusion), compressing the heart and interfering with its ability to pump blood.
• Skin and subcutaneous tissue (cutaneous hemangiosarcoma) — Skin hemangiosarcoma can appear as dark red or purple raised lesions. Cutaneous forms that are limited to the skin (dermal) have a better prognosis than those that develop in the tissue beneath the skin (subcutaneous or hypodermal).

Hemangiosarcoma can also develop in the liver, lungs, kidneys, brain, and bones, though these locations are less common. Regardless of the primary site, hemangiosarcoma is highly metastatic — it has usually spread to other organs by the time it is diagnosed. This aggressive behavior is what makes it such a challenging cancer to treat.

Causes and Risk Factors

The exact cause of hemangiosarcoma in dogs is not fully understood, but several risk factors have been identified through research and clinical observation.

Breed Predisposition

Certain breeds are significantly overrepresented in hemangiosarcoma diagnoses. German Shepherds are the most commonly affected breed, with some studies suggesting they have a two to five times higher risk compared to the general dog population. Golden Retrievers, Labrador Retrievers, Portuguese Water Dogs, Boxers, Doberman Pinschers, and Flat-Coated Retrievers are also at increased risk. This strong breed predisposition suggests a significant genetic component to the disease.

Age

Hemangiosarcoma is predominantly a cancer of middle-aged to older dogs. The average age at diagnosis is between nine and twelve years. While it can occur in younger dogs, this is uncommon.

Sun Exposure

Dermal (skin surface) hemangiosarcoma has been linked to chronic sun exposure, particularly in dogs with light-colored or thin coats and lightly pigmented skin. This form of the disease is more commonly seen in dogs that spend significant time outdoors in sunny climates. Breeds like Whippets, Italian Greyhounds, and white-coated dogs are at higher risk for sun-induced skin hemangiosarcoma.

Gender

Some studies have found a slightly higher incidence in male dogs compared to females, though the difference is not dramatic. Spayed females may have a somewhat higher risk compared to intact females, though research on this topic is ongoing and not yet conclusive.

Symptoms of Hemangiosarcoma

One of the most challenging aspects of hemangiosarcoma is that it often develops silently. Dogs may show no symptoms at all until the tumor ruptures or grows large enough to compress surrounding organs. The symptoms that do appear depend on the location of the primary tumor.

Splenic Hemangiosarcoma

The most dramatic presentation of splenic hemangiosarcoma is acute collapse due to internal bleeding from a ruptured tumor. Symptoms may include sudden weakness or collapse, pale gums, rapid heart rate, distended abdomen, and labored breathing. Some dogs experience intermittent episodes of weakness that resolve on their own — these “bleed-and-clot” episodes occur when a tumor bleeds briefly and then stops. These episodes may be the only warning sign before a catastrophic rupture.

More subtle symptoms of splenic hemangiosarcoma include decreased appetite, weight loss, lethargy, intermittent weakness, and a gradual enlargement of the abdomen.

Cardiac Hemangiosarcoma

When hemangiosarcoma develops in the heart, it can cause pericardial effusion — fluid accumulation in the sac surrounding the heart. This compresses the heart and prevents it from filling properly, a condition called cardiac tamponade. Symptoms include sudden collapse, muffled heart sounds, distended jugular veins, weakness, exercise intolerance, and rapid breathing. Cardiac tamponade is a medical emergency that requires immediate intervention.

Cutaneous Hemangiosarcoma

Skin hemangiosarcoma appears as dark red, purple, or black raised growths on the skin. They may bleed easily and can be mistaken for bruises or benign skin growths. Dermal lesions confined to the surface of the skin have the best prognosis of all hemangiosarcoma types. Subcutaneous lesions that develop in deeper tissue layers are more aggressive and have a poorer outlook.

General Symptoms

Regardless of location, dogs with hemangiosarcoma may show nonspecific signs including lethargy, decreased appetite, weight loss, anemia (pale gums), and increased respiratory rate. Because these symptoms are common to many conditions, hemangiosarcoma may not be immediately suspected.

Diagnosis

Diagnosing hemangiosarcoma typically involves a combination of physical examination, imaging, blood work, and ultimately tissue biopsy.

Physical examination — The veterinarian may detect a mass in the abdomen, an irregular heartbeat, muffled heart sounds, pale gums, or skin lesions during routine examination. In emergency situations, the primary finding may be signs of shock from internal bleeding.

Blood work — A complete blood count often reveals anemia (low red blood cell count), which occurs due to bleeding from the tumor. Thrombocytopenia (low platelet count) may also be present if the cancer is causing disseminated intravascular coagulation (DIC), a serious clotting disorder. Blood chemistry panels help assess organ function.

Imaging — Abdominal ultrasound is the most useful imaging tool for detecting splenic and liver masses. It can also identify free fluid in the abdomen, which suggests active bleeding. Echocardiography (cardiac ultrasound) is essential for detecting cardiac masses and pericardial effusion. Chest X-rays are performed to check for lung metastasis. Advanced imaging such as CT scans may be recommended for surgical planning.

Biopsy and histopathology — A definitive diagnosis of hemangiosarcoma requires microscopic examination of tumor tissue. Fine needle aspiration (using a needle to collect cells from a mass) is often unreliable for hemangiosarcoma because the tumors are composed largely of blood and may not yield enough diagnostic cells. Surgical biopsy or removal of the tumor followed by histopathology is typically necessary for a confirmed diagnosis.

It is important to note that not every splenic mass is hemangiosarcoma. Studies show that approximately one-third to two-thirds of splenic masses in dogs are malignant, and of those, hemangiosarcoma is the most common type. Benign masses including hematomas and nodular hyperplasia can appear similar on imaging.

Treatment Options

Treatment for hemangiosarcoma depends on the location and stage of the cancer, the dog’s overall health, and the owner’s goals for quality of life.

Emergency Stabilization

Many dogs with hemangiosarcoma first present in an emergency situation due to internal bleeding. Immediate treatment focuses on stabilizing the dog through intravenous fluids, blood transfusions, and management of shock. Pericardiocentesis — draining fluid from around the heart — may be performed for dogs with cardiac tamponade. Once the dog is stabilized, further diagnostic testing and treatment planning can proceed.

Surgery

Splenectomy (removal of the spleen) is the standard treatment for splenic hemangiosarcoma and is often performed as an emergency procedure when a bleeding mass is identified. Surgery alone can provide rapid improvement and immediate relief from the bleeding emergency. However, surgery alone typically provides a survival time of only one to three months because the cancer has usually already spread by the time of diagnosis.

For cardiac hemangiosarcoma, surgery is more complex and may involve removal of the tumor from the right atrium. This requires a skilled surgical team and carries higher risks. For skin hemangiosarcoma, wide surgical excision with clean margins can be curative for dermal lesions, while subcutaneous lesions may require more aggressive surgery.

Chemotherapy

Chemotherapy following surgery is the current standard of care for splenic and cardiac hemangiosarcoma. The most commonly used protocol is doxorubicin-based, administered intravenously every two to three weeks for five to six treatments. Chemotherapy after splenectomy extends median survival time to approximately four to six months, with some dogs surviving a year or longer.

Chemotherapy in dogs is generally better tolerated than in humans. Most dogs experience mild side effects including temporary nausea, decreased appetite, and mild lethargy for a day or two after treatment. Severe side effects occur in a small percentage of patients. Your veterinary oncologist will monitor your dog closely throughout treatment.

Metronomic Chemotherapy

Metronomic chemotherapy involves administering low doses of oral chemotherapy drugs on a continuous daily schedule rather than high-dose intravenous cycles. This approach targets the blood vessels that feed the tumor rather than the cancer cells directly. It is sometimes used as maintenance therapy after standard chemotherapy or as a palliative option for dogs that are not candidates for aggressive treatment.

Immunotherapy and Clinical Trials

Research into immunotherapy for canine hemangiosarcoma is ongoing and showing promising results. A Listeria-based vaccine developed at the University of Pennsylvania has shown potential to extend survival times significantly in some dogs. Clinical trials investigating new treatment approaches are available at many veterinary teaching hospitals and specialty centers. Participating in a clinical trial can give your dog access to cutting-edge treatments.

Prognosis and Survival Times

The prognosis for hemangiosarcoma varies significantly based on the type and stage of the cancer:

• Dermal hemangiosarcoma — When limited to the skin surface and completely excised, this form has the best prognosis. Many dogs are cured with surgery alone, with survival times of one to two years or longer being common.
• Splenic hemangiosarcoma, surgery alone — Median survival time is approximately one to three months.
• Splenic hemangiosarcoma, surgery plus chemotherapy — Median survival time is approximately four to six months. Approximately 10% to 20% of dogs survive beyond one year.
• Cardiac hemangiosarcoma — This form carries the poorest prognosis, with median survival times of approximately one to four months even with treatment.

These are median survival times, meaning half of dogs live longer and half live shorter than these figures. Individual variation can be significant, and some dogs significantly outlive expectations. Dogs with mast cell tumors or other concurrent cancers may have different treatment considerations and prognoses.

Supporting Your Dog Through Hemangiosarcoma

A hemangiosarcoma diagnosis is emotionally devastating, but there are many things you can do to support your dog’s quality of life during treatment.

Focus on quality of life. Work with your veterinarian to establish quality-of-life criteria specific to your dog. Consider factors like appetite, mobility, pain level, enjoyment of activities, and interaction with family members. Regularly assessing these factors helps you make informed decisions about continuing or adjusting treatment.

Provide excellent nutrition. Dogs with cancer benefit from high-quality, easily digestible food. Some veterinary oncologists recommend diets higher in protein and fat and lower in simple carbohydrates. Discuss dietary recommendations with your veterinary team.

Manage pain and discomfort. Your veterinarian can prescribe pain medication, anti-nausea drugs, and other supportive care to keep your dog comfortable. Do not hesitate to report any changes in behavior or comfort level between appointments.

Maintain routine. Dogs thrive on routine, and maintaining their normal schedule as much as possible provides comfort and stability. Continue regular walks (adjusted for energy level), meals at usual times, and normal interactions with the family.

Consider palliative care. If aggressive treatment is not appropriate for your dog, palliative care focused on comfort and quality of life is a valid and compassionate choice. This may include pain management, appetite stimulants, and supportive care to keep your dog comfortable for as long as possible.

Frequently Asked Questions About Hemangiosarcoma in Dogs

Can Hemangiosarcoma in Dogs Be Prevented?

There is currently no known way to prevent hemangiosarcoma in dogs. Because the disease has a strong genetic component, breeding decisions may play a role in reducing incidence over time. For skin hemangiosarcoma, limiting sun exposure — particularly for light-skinned dogs — may reduce risk. Regular veterinary check-ups that include abdominal palpation and blood work can sometimes detect the disease at an earlier stage, though early detection remains challenging.

How Is Hemangiosarcoma Different From Other Tumors?

Hemangiosarcoma is unique in several ways. It arises from blood vessel cells rather than the organ tissue itself, which means it can develop anywhere blood vessels exist. It is extremely aggressive and metastasizes early, often before the primary tumor is even detected. Unlike many other cancers, hemangiosarcoma tumors are fragile and prone to rupturing, which can cause acute internal bleeding. Other common cancers in dogs, such as mast cell tumors, have different biological behaviors and treatment approaches.

Should I Choose Surgery and Chemotherapy or Palliative Care?

This is a deeply personal decision that depends on many factors including the stage of the cancer, your dog’s age and overall health, quality-of-life considerations, and practical factors like treatment costs and your ability to manage the treatment schedule. There is no wrong answer. Surgery plus chemotherapy offers the best chance of extended survival time, but palliative care is a compassionate choice that focuses on comfort. Discuss all options thoroughly with your veterinary oncologist before deciding.

What Are the Warning Signs of Internal Bleeding?

Signs of internal bleeding from a ruptured hemangiosarcoma tumor include sudden weakness or collapse, pale or white gums, rapid breathing, distended abdomen, cold extremities, and a rapid but weak pulse. If you observe any of these signs, transport your dog to an emergency veterinary hospital immediately. Time is critical — internal bleeding can be fatal within hours without intervention.

Is Hemangiosarcoma Painful for Dogs?

The tumor itself may not be painful in its early stages. However, a ruptured tumor causing internal bleeding can cause significant abdominal pain and distress. As the cancer progresses and spreads, it can cause pain in affected organs. Dogs with hemangiosarcoma may also experience fatigue and malaise from anemia. Modern veterinary pain management can effectively address cancer-related pain, and keeping your dog comfortable should be a priority throughout the course of the disease.

Are There Any Promising New Treatments for Hemangiosarcoma?

Research into hemangiosarcoma treatment is active and producing encouraging results. Immunotherapy approaches, particularly cancer vaccines, have shown promise in clinical trials. Targeted therapies that attack the specific molecular pathways involved in hemangiosarcoma growth are being investigated. Metronomic chemotherapy protocols continue to be refined. If you are interested in the latest treatment options, consider consulting with a veterinary oncologist who can discuss clinical trials that may be available for your dog.